lipella.com (LIPO): Price to Earnings Adjusted for Growth Rate
Lipella Pharmaceuticals price action is tied to the success of drug repurposing and FDA approvals. The growth-adjusted P/E in the GURU.Markets interface displays this chart, where the 0.00 metric determines this level. The development of LP-10 for bladder cancer therapy is complemented by a strategy of outsourcing research to external CRO contractors to minimize operational risks.
Metric breakdowns and analytics for Lipella Pharmaceuticals (LIPO)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital Lipella Pharmaceuticals|LIPO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital lipella.com|LIPO - Company Debts|Debt to Book Capitalization Ratio Lipella|LIPO - Company Long-Term Debts|Short-Term Debt Volume Lipella Pharmaceuticals|Critical Liquidity Ratio lipella.com
- earnings and market ratios statistics:
LIPO - Net Profit|Expected Net Profit Lipella Pharmaceuticals|LIPO - Price to Earnings Ratio|Future Price to Earnings Lipella Pharma|LIPO - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipella|LIPO - Operating profit EBITDA|Net earnings per share (EPS TTM) Lipella Pharmaceuticals|LIPO - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months lipella.com|LIPO - Earnings per share growth in current year|Net earnings per share change forecast for next year Lipella Pharmaceuticals
Fundamental company analysis:Lipella Pharmaceuticals Inc LIPO
The PEG ratio is used for comparative asset analysis, as it correlates the market value of earnings with their growth rate, signaling an undervalued asset when the value falls below one. Given the management resource constraints at Lipella Pharmaceuticals (LIPO), the adjusted P/E-to-growth ratio allows for the separation of the micro-cap's fundamental potential from the speculative risk of a deep drawdown.
Competing companies
HLN (Haleon PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kenvue Corp KVUE|Verona Pharma Inc. (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|ligand.com - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company PLC - Growth-Adjusted Payback Ratio|ALVO (Alvotech Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liquidia Inc. LQDA|Price/Earnings to Growth Ratio Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio MannKind MNKD|Amphastar Pharmaceuticals Inc - Price/Earnings to Growth Ratio|Pacira - PEG Multiple|Growth-Adjusted Market Cap to Net Income ARS Corp SPRY|Theravance Biopharma (TBPH) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio AQST (aquestive.com)|SCPH (scPharmaceuticals, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tectonic TECX|Price/Earnings to Growth Ratio Tonix Pharmaceuticals Inc. (TNXP)|Price/Earnings to Growth Ratio SXTC (sxtchina.com)|Price/Earnings to Growth Ratio Eupraxia Pharmaceuticals Inc. EPRX|bioharvest.com - Price/Earnings to Growth Ratio|eXoZymes - PEG Multiple|ORMP - PEG Multiple|ENTX (enterabio.com) - Price/Earnings to Growth Multiple|MindWalk Therapeutics - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio ABVC BioPharma|cumberlandpharma.com - Market Cap to Earnings and Growth Ratio|PEG Multiple QNTM|FGEN (FibroGen Inc) - Growth-Adjusted Payback Ratio|PEG Multiple TELO (Telomir Pharma)|PEG Multiple Rani Therapeutics Holdings RANI|SNYR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio RLYB (Rallybio Corporation)|lexariabioscience.com (LEXX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Pulmatrix Inc|PTHL (Pheton Holdings Limited) - PEG Multiple|PEG Multiple Aptorum|PEG Multiple LYRA|Price/Earnings to Growth Multiple impactbiomedinc.com IBO|PEG Multiple TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. (YCBD) - Price to Earnings Adjusted for Growth Rate|PRFX: Price/Earnings to Growth Multiple|CYTO - PEG Multiple|OPTN (OptiNose, Inc.) - Price/Earnings to Growth Multiple|PIRS: Company Value to Earnings Growth Ratio|PROC (Procaps) - PEG Multiple|Petros Pharmaceuticals Inc (PTPI) - Growth-Adjusted Market Cap to Net Income|PEG Multiple QLI|Price/Earnings to Growth Multiple ACELYRIN Inc. SLRN|PEG Multiple TFFP (TFF Pharmaceuticals)
